bioAffinity Technologies Completes $2.6 Million Offering
bioAffinity Technologies, Inc. has successfully completed a significant financial milestone, closing its previously announced registered direct offering. This offering, notable for its $2.6 million in gross proceeds, signals progress for the biotechnology community, particularly in noninvasive cancer detection. WallachBeth Capital LLC facilitated this offering, acting as the sole placement agent, thereby reinforcing their role in connecting capital markets with innovative health solutions.
Details of the Direct Offering
The offering consisted of 2,048,294 shares of common stock priced at $1.30 per share. Alongside this, bioAffinity issued warrants that allow for the purchase of up to 2,662,782 shares with an exercise price of $1.50. These funds will serve crucial roles in enhancing the company's operational capabilities and advancing important projects.
Strategic Use of Proceeds
bioAffinity Technologies intends to channel the net proceeds from this offering primarily toward general corporate purposes, including the critical area of working capital. This decision underscores the company’s commitment to ensuring they remain at the forefront of biotechnological advancements aimed at cancer detection.
Role of WallachBeth Capital
As a key facilitators in this transaction, WallachBeth Capital LLC provided vital capital market and institutional execution services. Their expertise spans various financing methods, offering essential support to healthcare innovation initiatives. Their role in this specific offering showcases how strategic partnerships can foster growth within the biotech sector.
Investing in Future Technology
With their primary focus on developing noninvasive cancer detection methods, bioAffinity Technologies continues to address significant health challenges. By securing these funds, the company is well-equipped to enhance its research and development efforts, which could lead to groundbreaking advancements in early-stage cancer diagnostics.
Corporate Overview of bioAffinity Technologies
Founded on the principles of advancing healthcare through innovation, bioAffinity Technologies is dedicated to employing cutting-edge methodologies for cancer detection. Their commitment to improving diagnostic approaches positions them as significant players in solving pressing medical challenges faced by society today.
Frequently Asked Questions
What was the total amount raised by bioAffinity Technologies?
bioAffinity Technologies raised a total of $2.6 million through their recent offering.
Who acted as the placement agent for this offering?
WallachBeth Capital LLC acted as the sole placement agent for bioAffinity Technologies' offering.
What will the proceeds from the offering be used for?
The proceeds will primarily be used for general corporate purposes and working capital.
What is the primary focus of bioAffinity Technologies?
bioAffinity Technologies focuses on noninvasive tests for detecting early-stage cancer.
What exercises price was set for the common warrants?
The common warrants have an exercise price of $1.50 per share.
